Navigation Links
When It Comes to Natural Remedies for Hormonal Balance, the Proof Is in the Clinical Research
Date:6/12/2009

Femmenessence: Proven to Regulate Hormone Levels in Women

SAN FRANCISCO, June 12 /PRNewswire/ -- Women approaching and exiting menopause are in a bind. As hormone levels fluctuate and decline, they experience a range of uncomfortable symptoms that can include hot flashes, night sweats, mood decline, and loss of libido. As common as these symptoms are, women's options for relief are limited. Researchers reported in 2002 that the hormone replacement therapy Prempro(R), which introduces foreign estrogens, obtained from pregnant mare's urine, into a woman's body, increased rates of breast cancer and stroke, (per JAMA 2002; 288:321-333.) causing American women to reject the drug en masse. While natural products that promise relief from menopausal symptoms abound, few have success rates higher than 50% and none have been clinically proven to regulate hormone levels; with one exception: Natural Health International's Femmenessence, made from the proprietary ingredient Maca-GO(R), www.naturalhi.com, a concentrated organically certified, proprietary formulation of the Peruvian herb maca.

Hormones are the body's directors, controlling the activity of cells and organs, affecting much more than just menopausal symptoms. "Hormones are profoundly important to a woman's health - hormones affect a woman's mood and cognitive function, they directly affect a woman's bone density, and hormones are without a doubt the most important factor of a woman's cardiovascular health," explains James Frame, CEO of Natural Health International (NHI), a vertically integrated San Francisco based health and dietary supplement company.

The subject of four published studies, the Femmenessence line includes two hormone-balancing products for women entering or leaving "the change of life": MacaLife(R) for peri-menopausal women experiencing hormonal fluctuations, and MacaPause(R) for post-menopausal women experiencing loss of hormone production. Peri-menopause is the 1-10 year period in which a woman's body transitions into menopause.

Femmenessence does not introduce any foreign hormones into the system. It simply supports the body's ability to balance (either increase or decrease) levels of its own hormones. Passing stringent pharmacology, toxicology and double blind placebo controlled clinical trials for health and safety, Femmenessence is as safe and side effect-free as your own hormones have been throughout your life.

However, the products are very different to other Maca based products and are not interchangeable, both due to the concentrated levels of the full spectrum of active constituents, and multiple phenotypes. "Something a lot of people don't realize is that there are 13 different phenotypes within Maca, and amazingly some of those phenotypes actually elicit different physiological effects," said Frame. NHI researched what the different phenotypes do and formulated Femmenessence MacaLife(R) and Femmenessence MacaPause(R) accordingly. MacaLife(R) is formulated for relief of menopausal symptoms, while MacaPause(R) is focused on supporting foundational health after menopause, such as heart health, bone health, mental health and hormonal balance.

About Natural Health International

Natural Health International was founded in 1997 as a raw material supply business in Sydney, Australia, that today has expanded internationally and merged with a leading research and development company. One of the few dietary supplement companies in the world that is vertically integrated, NHI grows its own herbs and maintains complete control over the manufacturing and distribution of its products. All NHI products are packaged in oxygen-barrier blister packs, recycled light-proof cardboard boxes, and are printed with vegetable ink. NHI products are available through selected health food stores such as Whole Foods, PCC, NRG and Pharmaca, as well as online at www.naturalhi.com.

For more information on NHI, the Femmenessence product line, or media related inquiries, contact Jennifer Bryan 805-962-1347 or at jbryan@christiecomm.com.


'/>"/>
SOURCE Natural Health International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
2. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
3. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
4. Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
5. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
6. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
7. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
8. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
9. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
10. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
11. Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , January 19, 2017 ... ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... Published recently in a ... peer-reviewed journal from touchONCOLOGY, an article by ...
(Date:1/19/2017)... CAMBRIDGE, England , January 19, 2017 ... MedImmune and Otsuka in the Milner Therapeutics Consortium   ... academic scientists in Cambridge   ... Inc. (NYSE: PFE ) as a partner ... join the Consortium, which enables the efficient transfer of ...
(Date:1/19/2017)... 2017  ViewRay, Inc. (Nasdaq: VRAY ... clinical MRI-guided radiation therapy system, announced today that it ... million through a private placement of its common ... financing and was joined by certain of ViewRay,s ... Venture Partners, and an additional new institutional investor, ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... ... agency which serves Lawrenceville, New Jersey and the surrounding area, is inaugurating ... lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease or motor neurone ...
(Date:1/19/2017)... , ... January 18, 2017 , ... The CHP suggests ... during a rain storm by slowing down and increasing the space between themselves and ... Los Angeles based car accident attorney Raymond R. Hassanlou notes that, rain or shine, ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... styled text designs that will simplify the editing process for all media productions," ... Basics is a package of 30 simplistically styled self-animating paragraphs designed for multi-lined ...
(Date:1/18/2017)... Austin, TX (PRWEB) , ... January 18, 2017 , ... ... million people opened a global discussion about the benefits of fidgeting to relieve stress ... Lyon and Jym Daniel. Their Think Ink Pen had just completed a successful ...
(Date:1/18/2017)... SAN JOSE, Calif, USA; and SHANGHAI, China – , ... ... January 18, 2017 -- Global public health organization NSF International ... V (pentavalent arsenic) to NSF/ANSI 53: Drinking Water Treatment Units ... treatment units. This certification verifies that MicroCeramics’ NanoNose Pitcher Filter ...
Breaking Medicine News(10 mins):